Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons G.S. van Zuiden, MSc

Publicaties

Fatigue in primary Sjögren's syndrome is associated with an objective decline in physical performance, pain and depression

Long-term abatacept treatment for 48 weeks in patients with primary Sjogren's syndrome: The open-label extension phase of the ASAP-III trial

Patient acceptable symptom state (PASS) in patients with primary Sjögren's syndrome in daily clinical practice

Patient Acceptable Symptom State (PASS) in patients with primary Sjögren's syndrome in daily clinical practice

Reduced central nervous system drive in primary Sjögren’s syndrome is associated with objective decline in motor performance and self-reported fatigue

Clinical Phenotyping of Primary Sjogren Syndrome Patients Using Salivary Gland Ultrasonography: Data From the RESULT Cohort

Abacept treatment for patients with early active primary Sjögren's syndrome: OPEN-LABEL EXTENSION PHASE OF A RANDOMIZED CONTROLLED PHASE III TRIAL

Abatacept treatment for patients with early active primary Sjogren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)

Self-reported Fatigue in Patients with Primary Sjogren's Syndrome Is Associated with an Objective Decline in Physical Performance and Symptoms of Pain and Depression

ABATACEPT TREATMENT OF PATIENTS WITH EARLY ACTIVE PRIMARY SJOGREN'S SYNDROME - A RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED PHASE III-STUDY (ASAP-III)

Lees meer